A pivotal clinical trial for renal denervation to treat hypertension is underway on the heels of a pair of recent clinical trial results from Medtronic plc. The company had a phase III failure in this field in 2014, but is convinced that it has altered its approach sufficiently to succeed this time around. The first pivotal trial is in hypertension patients who are not on any medication; potential additional trials in the pivotal program remain under consideration. Read More
